Authors: Birner, P Oberhuber, G Stani, J Reithofer, C Samonigg, H Hausmaninger, H Kubista, E Kwasny, W Kandioler-Eckersberger, D Gnant, M Jakesz, R

Citation: P. Birner et al., Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer, CLIN CANC R, 7(6), 2001, pp. 1669-1675

Authors: Janschek, E Kandioler-Eckersberger, D Ludwig, C Kappel, S Wolf, B Taucher, S Rudas, M Gnant, M Jakesz, R

Citation: E. Janschek et al., Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer, BREAST CANC, 67(1), 2001, pp. 1-8

Authors: Kandioler-Eckersberger, D Ludwig, C Rudas, M Kappel, S Janschek, E Wenzel, C Schlagbauer-Wadl, H Mittlbock, M Gnant, M Steger, G Jakesz, R

Citation: D. Kandioler-eckersberger et al., TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients, CLIN CANC R, 6(1), 2000, pp. 50-56

Authors: Kandioler-Eckersberger, D Kappel, S Mittlbock, M Dekan, G Ludwig, C Janschek, E Pirker, R Wolner, E Eckersberger, F

Citation: D. Kandioler-eckersberger et al., The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer, J THOR SURG, 117(4), 1999, pp. 744-750

Authors: Brodowicz, T Wiltschke, C Kandioler-Eckersberger, D Grunt, TW Rudas, M Schneider, SM Hejna, M Budinsky, A Zielinski, CC

Citation: T. Brodowicz et al., Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids, BR J CANC, 80(9), 1999, pp. 1350-1358